Functional Neurosurgery: An Overview
On this page
Direct answer
Circuits, not lesions, are the operative target of functional neurosurgery: deep brain stimulation delivers high-frequency stimulation (classically around 130 Hz, 60 microsecond pulse width, gradually titrated amplitude) through stereotactically placed electrodes to modulate pathological network activity — the subthalamic nucleus and globus pallidus internus for Parkinson's disease motor complications, the ventral intermediate nucleus of the thalamus for tremor, the pallidum for dystonia, and the anterior thalamus (supported by the SANTE trial) or responsive closed-loop stimulation for epilepsy. The field spans lesioning (thalamotomy, pallidotomy, cingulotomy) where hardware and cost preclude stimulation, epilepsy resection — the Wiebe randomised trial of temporal lobectomy found 58 per cent of surgical patients seizure-free at one year against 8 per cent on medication, one of the strongest results in all of surgery — and pain procedures from microvascular decompression to cordotomy for cancer pain. Patient selection is the discipline: for movement disorders, the levodopa response is the best predictor of stimulation benefit, and axial symptoms, dysautonomia and cognition improve little.
What you must remember
- Target-disease pairs to recite: subthalamic nucleus and globus pallidus internus for Parkinson's motor fluctuations and dyskinesia; ventral intermediate thalamus for essential tremor and cerebellar outflow tremor; globus pallidus internus for dystonia (improving over months); anterior thalamic nucleus and responsive neurostimulation for focal epilepsy; nucleus accumbens/ventral capsule for obsessive-compulsive disorder under humanitarian programmes.
- Stimulation grammar: around 130 Hz, roughly 60 microseconds pulse width, amplitude titrated against benefit and side effects, staged bilateral implantation, frame-based stereotaxy with microelectrode recording and test stimulation.
- Selection rules for Parkinson DBS: levodopa-responsive, disabling motor fluctuations or dyskinesia, preserved cognition and psychiatric stability, no major axial dominance — "the best predictor of DBS response is the levodopa response" is the quotable sentence.
- Epilepsy surgery evidence: drug resistance defined as failure of two appropriate antiepileptic drugs; the Wiebe randomised trial — 58 versus 8 per cent seizure-free at one year for temporal lobectomy over medical management — with the Engel classification grading outcome.
- Lesioning in Indian practice: thalamotomy and pallidotomy remain relevant where a stimulator's cost and follow-up are out of reach — one lesion, no hardware, no battery replacements — a selection driven by access as much as anatomy.
- Pain portfolio: cordotomy for unilateral cancer pain, dorsal root entry zone lesioning for brachial plexus avulsion, microvascular decompression for trigeminal neuralgia, and neuromodulation (spinal cord stimulation) for neuropathic pain.
Candidacy work-up for Parkinson DBS
A 61-year-old man has had Parkinson's disease for eleven years; his medication windows have collapsed into disabling "off" periods and peak-dose dyskinesia, though a levodopa challenge in clinic restores near-normal gait and dexterity. The work-up proceeds as a checklist: a formal levodopa challenge quantifying the motor Unified Parkinson's Disease Rating Scale improvement (a robust percentage improvement predicts surgical benefit); neuropsychological testing to exclude dementia, because stimulation will not rescue a failing mind and may worsen confusion; psychiatric screening for untreated depression or impulse-control disorder; brain MRI excluding significant atrophy or vascular disease and enabling stereotactic planning; and a realistic conversation — tremor, rigidity, fluctuations and dyskinesia improve; freezing of gait, falling, dysphagia, hypophonia and autonomic failure do not.
At surgery, subthalamic targets are acquired by frame-based stereotaxy with MRI, refined by microelectrode recording and test stimulation for benefit and side effects — tetani, diplopia, mood — before permanent electrodes, extensions and pacemaker are implanted, staged or same-sitting.
Contrast the essential-tremor patient with bilateral disabling tremor: the ventral intermediate nucleus is the target, benefit is immediate, and the counselling emphasises suppression of tremor, not the disease.
High-yield viva angles
Three questions recur. "Why DBS over lesioning?" — reversibility, adjustability, bilaterality without the cumulative deficit of paired ablations, at the cost of hardware, infection risk, battery replacements and expense — and in India the honest reversal: lesioning survives on economics. "Who should not be offered DBS?" — dementia, refractory psychiatric disease, and Parkinson-plus syndromes whose poor levodopa response betrays them. "What is the strongest evidence in functional neurosurgery?" — epilepsy surgery, by the Wiebe trial's 58 versus 8 per cent; the field's irony is that its most curative operation is its least technological.
Frequently asked questions
Which DBS targets serve which disorders?
Subthalamic nucleus and globus pallidus internus for Parkinson's disease, ventral intermediate thalamus for tremor, globus pallidus internus for dystonia, and anterior thalamus or responsive stimulation for epilepsy.
What predicts a good outcome after DBS for Parkinson's disease?
A robust levodopa response on challenge testing, with preserved cognition and absence of dominant axial or non-motor symptoms.
What did the Wiebe trial show for temporal lobectomy?
Fifty-eight per cent of surgical patients were free of disabling seizures at one year compared with 8 per cent on continued medical therapy.
What are typical deep brain stimulation parameters?
Frequency around 130 Hz with pulse width near 60 microseconds and amplitude titrated individually, delivered continuously through implanted electrodes.
Why do lesioning procedures persist in Indian practice?
Thalamotomy and pallidotomy achieve durable unilateral benefit in one session without hardware cost or lifelong follow-up, fitting access and economic realities that stimulators often do not.